Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Consolidated Statements of Operations

v3.24.3
Unaudited Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Operating expenses:        
Research and development $ 2,327 $ 907 $ 6,080 $ 5,149
Research and development – licenses acquired 0 0 0 4,230
General and administrative 829 1,161 3,607 3,042
Loss from operations (3,156) (2,068) (9,687) (12,421)
Other income (expense):        
Interest income 51 9 152 104
Financing costs – warrant liabilities 0 0 0 (332)
Loss on settlement of common stock warrant liabilities 0 0 (759) 0
Change in fair value of warrant liabilities 18 2,572 157 1,544
Total other income (expense) 69 2,581 (450) 1,316
Net income (loss) (3,087) 513 (10,137) (11,105)
Net loss attributable to non-controlling interests (11) (13) (29) (88)
Net income (loss) attributable to Avenue (3,076) 526 (10,108) (11,017)
Net income (loss) attributable to common stockholders $ (3,076) $ 526 $ (18,918) $ (11,017)
Net income (loss) per common share attributable to common stockholders, basic and diluted (in dollars per share) $ (1.92) $ 4.86 $ (17.27) $ (115.55)
Weighted average number of common shares outstanding, basic and diluted (in shares) 1,600,189 108,210 1,095,180 95,348